Drugs and Leads from the Ocean Through Biotechnology References 727
Part F | 29
29.60
G.R. Pettit: Progress in the discovery of biosynthetic anticancer drugs, J. Nat. Prod. 59, 812–821
(1996)
29.61
R.L. Berkow, L. Schlabach, R. Dodson, W.H. Benjamin, G.R. Pettit, P. Rustagi, A.S. Kraft: vivo
administration of the anticancer agent bryostatin
1 activates platelets and neutrophils and modulates protein kinase C activity, Cancer Res. 53,
2810–2815 (1993)
29.62
Z.B. Ma Hu, W.L. Uphoff, C.C.M. Lanotte,
H.G. Drexler: Modulation of gene-expression
in the acute promyelocytic leukemia-cell line
Nb4, Leukemia 7, 1817–1823 (1993)
29.63
R. Mutter, M. Wills: Chemistry and clinical biology
of the bryostatins, Bioorg. Med. Chem. 8, 1841–
1860 (2000)
29.64
J.A. Ajani: Multi-center Phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in
patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma, Invest.
New Drugs 24, 353–357 (2006)
29.65
M.L. Varterasian, P.A. Pemberton, K. Hulburd,
D.H. Rodriguez, A. Murgo, A.M. Al-Katib: Phase
II study of bryostatin 1 in patients with relapsed
multiple myeloma, Invest. New Drugs 19, 245–247
(2001)
29.66
P.F. Hickman, G.J. Kemp, C.H. Thompson, A.J. Salisbury, K. Wade, A.L. Harris, G.K. Radda: Bryostatin 1, a novel antineoplastic agent and protein
kinase C activator, induces human myalgia and
muscle metabolic defects: A 31P magnetic resonance spectroscopic study, Br. J. Cancer 72(4),
998–1003 (1995)
29.67
K.S. Moore, S. Wehrli, H. Roder, M. Rogers,
J.N. Forrest Jr., D. McCrimmon, M. Zasloff:
Squalamine: An aminosterol antiboitic from the
shark, Proc. Natl. Acad. Sci. 90(4), 1354–1358
(1993)
29.68
S.L. Wehrli, K.S. Moore, H. Roder, S. Durell, M. Zasloff: Structure of the novel steroidal antibiotic,
Steroids 58(8), 370–378 (1993)
29.69
T.A. Ciulla, M.H. Criswell, R.P. Danis, J.I. Williams,
M.P. McLane, K.J. Holroyd: Squalamine lactate
reduces choroidal neovascularization in a laserinjury model in the rat, Retina 23(6), 808–814
(2003)
29.70
V.A. Stonik: Marine natural products: A way to
new drug, Acta Nat. 2, 15–25 (2009)
29.71
K.L. Rinehart Jr., J.B. Gloer, R.G. Hughes,
H.E. Renis, J.P. McGovren, E.B. Swynenberg, D.A. Stringfellow, S.L. Kuentzel, L.H. Li:
Didemnins: Antiviral and antitumor depsipeptides from a Caribbean tunicate, Science 212,
933–935 (1981)
29.72
K. Rinehart: Antitumor compounds from tunicates, Med. Res. Rev. 1, 1–27 (2003)
29.73
R. Talpir, Y. Benayahu, Y. Kashman, L. Pannell,
M. Schleyer: Hemiasterlin and geodiamolide TA:
Two new cytotoxic peptides from the marine
sponge Hemiasterella minor (Kirkpatrick), Tetrahedron Lett. 35, 4453–4456 (1994)
29.74
G. Kuznetsov, K. TenDyke, M.J. Towle, H. Cheng,
J. Liu, J.P. Marsh, S.E. Schiller, M.R. Spyvee,
H. Yang, B.M. Seletsky, C.J. Shaffe, V. Marceau,
Y. Yao, E.M. Suh, S. Campagna, F.G. Fang,
J.J. Kowalczyk, B.A. Littlefield: Tubulin-based
antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product
the miasterlin, Mol. Cancer Ther. 8, 2852–2860
(2009)
29.75
N. Zojwalla, C.H. Takimoto, A.G. Lucarelli, R. Clark,
A.C. Mita, M.M. Mita, O. Romero, E.L. Schuck,
I. Krivelevich, C.J. Sweeney: A phase I trial of E7974
administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies, J. Clin.
Oncol. 25(20), 2543 (2007)
29.76
M.V. De Souza: (C)-discodermolide: A marine
natural product against cancer, Sci. World J. 4,
415–436 (2004)
29.77
R.E. Longley, D. Caddigan, D. Harmody, M. Gunasekera, S.P. Gunasekera: Discodermolide a new,
marine-derived immunosuppressive compound.
I. In vitro studies, Transplantation 52, 650–656
(1991)
29.78
R.E. Longley, D. Caddigan, D. Harmody, M. Gunasekera, S.P. Gunasekera: Discodermolide a new,
marine-derived immunosuppressive compound.
II. In vivo studies, Transplantation 52, 656–661
(1991)
29.79
R.E. Longley, S.P. Gunasekera, D. Faherty,
J. McLane, F. Dumont: Immuno suppression by
discodermolide, Ann. NY Acad. Sci. 696, 94–107
(1993)
29.80
J.G. Chen, S.B. Horwitz: Differential mitotic
responses to microtubule stabilizing and
destabilizing drugs, Cancer Res. 62, 1935–1938
(2002)
29.81
L.E. Bröke, C. Huisman, C.G. Ferreira, J.A. Rodriguez, F.A. Kruyt, G. Giaccone: Late activation
of apoptotic pathways plays a negligible role in
mediating the cytotoxic effects of discodermolide
and epothilone B in non-small cell lung cancer
cells, Cancer Res. 62, 4081–4088 (2002)
29.82
S. Honore, K. Kamath, D. Braguer, L. Wilson,
C. Briand, M.A. Jordan: Suppression of microtubule dynamics by discodermolide by a novel
mechanism is associated with mitotic arrest and
inhibition of tumor cell proliferation, Mol. Cancer
Ther. 2, 1303–1311 (2003)
29.83
G.R. Pettit: The dolastatins, Fortschr. Chem. Org.
Naturst. 70, 1–79 (1997)
29.84
D.J. Triggle: Drug discovery and delivery in
the 21st century, Med. Princ. Pract. 16, 1–14
(2007)
29.85
G.R. Pettit, Y. Kamano, C.L. Herald, A.A. Tuinman, F.E. Boettner, K. Haruhisa, J.M. Schmidt,
L. Baczynsky, B. Kenneth, T.R. Bontems: The
isolation and structure of a remarkable ma-
Part F | 29
29.60
G.R. Pettit: Progress in the discovery of biosynthetic anticancer drugs, J. Nat. Prod. 59, 812–821
(1996)
29.61
R.L. Berkow, L. Schlabach, R. Dodson, W.H. Benjamin, G.R. Pettit, P. Rustagi, A.S. Kraft: vivo
administration of the anticancer agent bryostatin
1 activates platelets and neutrophils and modulates protein kinase C activity, Cancer Res. 53,
2810–2815 (1993)
29.62
Z.B. Ma Hu, W.L. Uphoff, C.C.M. Lanotte,
H.G. Drexler: Modulation of gene-expression
in the acute promyelocytic leukemia-cell line
Nb4, Leukemia 7, 1817–1823 (1993)
29.63
R. Mutter, M. Wills: Chemistry and clinical biology
of the bryostatins, Bioorg. Med. Chem. 8, 1841–
1860 (2000)
29.64
J.A. Ajani: Multi-center Phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in
patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma, Invest.
New Drugs 24, 353–357 (2006)
29.65
M.L. Varterasian, P.A. Pemberton, K. Hulburd,
D.H. Rodriguez, A. Murgo, A.M. Al-Katib: Phase
II study of bryostatin 1 in patients with relapsed
multiple myeloma, Invest. New Drugs 19, 245–247
(2001)
29.66
P.F. Hickman, G.J. Kemp, C.H. Thompson, A.J. Salisbury, K. Wade, A.L. Harris, G.K. Radda: Bryostatin 1, a novel antineoplastic agent and protein
kinase C activator, induces human myalgia and
muscle metabolic defects: A 31P magnetic resonance spectroscopic study, Br. J. Cancer 72(4),
998–1003 (1995)
29.67
K.S. Moore, S. Wehrli, H. Roder, M. Rogers,
J.N. Forrest Jr., D. McCrimmon, M. Zasloff:
Squalamine: An aminosterol antiboitic from the
shark, Proc. Natl. Acad. Sci. 90(4), 1354–1358
(1993)
29.68
S.L. Wehrli, K.S. Moore, H. Roder, S. Durell, M. Zasloff: Structure of the novel steroidal antibiotic,
Steroids 58(8), 370–378 (1993)
29.69
T.A. Ciulla, M.H. Criswell, R.P. Danis, J.I. Williams,
M.P. McLane, K.J. Holroyd: Squalamine lactate
reduces choroidal neovascularization in a laserinjury model in the rat, Retina 23(6), 808–814
(2003)
29.70
V.A. Stonik: Marine natural products: A way to
new drug, Acta Nat. 2, 15–25 (2009)
29.71
K.L. Rinehart Jr., J.B. Gloer, R.G. Hughes,
H.E. Renis, J.P. McGovren, E.B. Swynenberg, D.A. Stringfellow, S.L. Kuentzel, L.H. Li:
Didemnins: Antiviral and antitumor depsipeptides from a Caribbean tunicate, Science 212,
933–935 (1981)
29.72
K. Rinehart: Antitumor compounds from tunicates, Med. Res. Rev. 1, 1–27 (2003)
29.73
R. Talpir, Y. Benayahu, Y. Kashman, L. Pannell,
M. Schleyer: Hemiasterlin and geodiamolide TA:
Two new cytotoxic peptides from the marine
sponge Hemiasterella minor (Kirkpatrick), Tetrahedron Lett. 35, 4453–4456 (1994)
29.74
G. Kuznetsov, K. TenDyke, M.J. Towle, H. Cheng,
J. Liu, J.P. Marsh, S.E. Schiller, M.R. Spyvee,
H. Yang, B.M. Seletsky, C.J. Shaffe, V. Marceau,
Y. Yao, E.M. Suh, S. Campagna, F.G. Fang,
J.J. Kowalczyk, B.A. Littlefield: Tubulin-based
antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product
the miasterlin, Mol. Cancer Ther. 8, 2852–2860
(2009)
29.75
N. Zojwalla, C.H. Takimoto, A.G. Lucarelli, R. Clark,
A.C. Mita, M.M. Mita, O. Romero, E.L. Schuck,
I. Krivelevich, C.J. Sweeney: A phase I trial of E7974
administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies, J. Clin.
Oncol. 25(20), 2543 (2007)
29.76
M.V. De Souza: (C)-discodermolide: A marine
natural product against cancer, Sci. World J. 4,
415–436 (2004)
29.77
R.E. Longley, D. Caddigan, D. Harmody, M. Gunasekera, S.P. Gunasekera: Discodermolide a new,
marine-derived immunosuppressive compound.
I. In vitro studies, Transplantation 52, 650–656
(1991)
29.78
R.E. Longley, D. Caddigan, D. Harmody, M. Gunasekera, S.P. Gunasekera: Discodermolide a new,
marine-derived immunosuppressive compound.
II. In vivo studies, Transplantation 52, 656–661
(1991)
29.79
R.E. Longley, S.P. Gunasekera, D. Faherty,
J. McLane, F. Dumont: Immuno suppression by
discodermolide, Ann. NY Acad. Sci. 696, 94–107
(1993)
29.80
J.G. Chen, S.B. Horwitz: Differential mitotic
responses to microtubule stabilizing and
destabilizing drugs, Cancer Res. 62, 1935–1938
(2002)
29.81
L.E. Bröke, C. Huisman, C.G. Ferreira, J.A. Rodriguez, F.A. Kruyt, G. Giaccone: Late activation
of apoptotic pathways plays a negligible role in
mediating the cytotoxic effects of discodermolide
and epothilone B in non-small cell lung cancer
cells, Cancer Res. 62, 4081–4088 (2002)
29.82
S. Honore, K. Kamath, D. Braguer, L. Wilson,
C. Briand, M.A. Jordan: Suppression of microtubule dynamics by discodermolide by a novel
mechanism is associated with mitotic arrest and
inhibition of tumor cell proliferation, Mol. Cancer
Ther. 2, 1303–1311 (2003)
29.83
G.R. Pettit: The dolastatins, Fortschr. Chem. Org.
Naturst. 70, 1–79 (1997)
29.84
D.J. Triggle: Drug discovery and delivery in
the 21st century, Med. Princ. Pract. 16, 1–14
(2007)
29.85
G.R. Pettit, Y. Kamano, C.L. Herald, A.A. Tuinman, F.E. Boettner, K. Haruhisa, J.M. Schmidt,
L. Baczynsky, B. Kenneth, T.R. Bontems: The
isolation and structure of a remarkable ma-